Alliancebernstein L.P. Pmv Pharmaceuticals, Inc. Transaction History

Alliancebernstein L.P.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$1.23 - $6.6 $3,653 - $19,602	-2,970 Reduced 5.55%	50,500 $156,000
Q3 2023 Nov 14, 2023	BUY	$6.01 - $8.93 $26,323 - $39,113	4,380 Added 8.92%	53,470 $328,000
Q2 2023 Aug 15, 2023	BUY	$3.94 - $6.27 $10,204 - $16,239	2,590 Added 5.57%	49,090 $307,000
Q1 2023 May 15, 2023	BUY	$4.77 - $9.16 $24,803 - $47,632	5,200 Added 12.59%	46,500 $221,000
Q3 2022 Nov 15, 2022	BUY	$11.4 - $17.18 $107,160 - $161,492	9,400 Added 29.47%	41,300 $491,000
Q2 2022 Aug 15, 2022	BUY	$9.23 - $22.43 $142,142 - $345,422	15,400 Added 93.33%	31,900 $455,000
Q4 2021 Feb 14, 2022	BUY	$19.99 - $30.24 $65,967 - $99,792	3,300 Added 25.0%	16,500 $381,000
Q3 2021 Nov 10, 2021	SELL	$26.84 - $36.58 $166,408 - $226,796	-6,200 Reduced 31.96%	13,200 $393,000
Q2 2021 Jul 30, 2021	BUY	$28.01 - $36.01 $268,896 - $345,696	9,600 Added 97.96%	19,400 $663,000
Q1 2021 May 06, 2021	BUY	$30.66 - $49.5 $15,330 - $24,750	500 Added 5.38%	9,800 $322,000
Q4 2020 Feb 08, 2021	BUY	$31.86 - $61.51 $296,298 - $572,043	9,300 New	9,300 $572,000

41.9M

3.1K

1.7K

Ticker PMVP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,622,600
Market Cap $73.5M
Description
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also d...

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

Stay updated on Alliancebernstein L.P. with notifications on news.